Campania shows a slight improvement when comparing data from the first four months of 2025 with the same period this year, ...

Celcuity shares dropped over 25% despite Phase 3 VIKTORIA-1 data confirming gedatolisib's best-in-class efficacy. Click here ...

WASHINGTON, D.C. — Cancer researchers highlighted several treatment breakthroughs during their annual summit in Chicago that ...

R&D expenses totaled $20.7 million, down from $33.2 million, primarily due to lower Alzheimer's trial costs. Impairment -- A ...

Go to <a href="https://ground.news/briggs">https://ground.news/briggs</a> for a better way to stay informed. Subscribe for 40 ...

We hope you've had a chance to review the press release we issued after market close in the U.S. today, announcing the positive top-line results of the Phase III ABTECT Maintenance trial. Joining me ...

A growing body of epidemiological evidence points to an inverse relationship between cancer and Alzheimer’s disease (AD): individuals with a cancer ...

Background A resemblance of pancreatic tumours to their native tissue architecture remains largely unexplored, while it may ...

OverviewThe global urology surgical instruments market is set to experience steady growth, with an anticipated compound ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced it will ...

Researchers Discover Surprising Brain Changes Linked to Intermittent Fasting Weight loss may not begin in the stomach ...